FORM PTO-1449
(R v. 2-32)U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

Serial No.

01-1720

09/993,211

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

Applicant:

Asp, et al.

Filing Date:

November 16, 2001

Group:

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appr priat

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translati n	
					Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

1.	Imondi, et al., "Dose-Response Relationship of Dexrazoxane for Prevention of Doxorubicin-Induced Cardiotoxicity in Mice, Rats and Dogs", <i>Cancer Research</i> , 56, pp. 4200-4204, 1996
2.	Tetef, et al., "Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane in Patients with Advanced Malignancies", <i>Clinical Cancer Research</i> , Vol. 7, pp. 1569-1576, 2001
3.	Keefe, "Anthracycline-Induced Cardiomyopathy", <i>Seminars in Oncology</i> , Vol. 28, No. 4, Suppl. 12, pp. 2-7, 2001
4.	Herman, et al., "Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats", <i>Cancer Chemother Pharmacol</i> , 45, pp. 329-334, 2000
5.	Della Torre, et al., "Cardioprotection by dexrazoxane in rats treated with doxorubicin and paclitaxel", <i>Cancer Chemother Pharmacol</i> , 44, pp. 138-142, 1999
6.	Speyer, et al., "Strategies for Reduction of Anthracycline Cardiac Toxicity", <i>Seminars in Oncology</i> , Vol. 25, No. 5, pp. 525-537, 1998
7.	Chvetzoff, et al., "Prévention de la toxicité", <i>La Presse Médicale</i> , 27, no. 39, pp. 2106-2112, 1998 (including English abstract)
8.	Herman, et al., "Preclinical Animal Models of Cardiac Protection from Anthracycline-Induced Cardiotoxicity", <i>Seminars in Oncology</i> , Vol. 25, No. 4, Suppl. 10, pp. 15-21, 1998
9.	Swain, et al., "Delayed Administration of Dexrazoxane Provides Cardioprotection for Patients with Advanced Breast Cancer Treated with Doxorubicin-Containing Therapy", <i>Journal of Clinical Oncology</i> , Vol. 15, No. 4, pp. 1333-1340, 1997

Amended for 7/24/05




	Pouna, et al., "Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention", <i>British Journal of Pharmacology</i> , Vol. 117, pp. 1593-1599, 1996
	Venturini, et al., "Multicenter Randomized Controlled Clinical Trial to Evaluate Cardioprotection of Dexrazoxane Versus No Cardioprotection in Women Receiving Epirubicin Chemotherapy for Advanced Breast Cancer", <i>Journal of Clinical Oncology</i> , Vol. 14, No. 12, pp. 3112-3120, 1996
12.	Dorr, "Cytoprotective Agents for Anthracyclines", <i>Seminars in Oncology</i> , Vol. 23, No. 4, Suppl. 8, pp. 23-34, 1996
13.	Shan, et al., "Anthracycline-Induced Cardiotoxicity", <i>Ann Intern Med.</i> , 125:47-58, 1996
14.	Cook-Bruns, "Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer", <i>Oncology</i> , 61 (suppl 2):58-66, 2001
15.	Winer, et al., "New Combinations with Herceptin® in Metastatic Breast Cancer", <i>Oncology</i> , 61 (suppl 2):50-57, 2001
16.	Ewer, et al., "Cardiotoxicity in Patients Receiving Trastuzumab (Herceptin): Primary Toxicity, Synergistic or Sequential Stress, or Surveillance Artifact?", <i>Seminars in Oncology</i> , Vol. 26, No. 4, Suppl. 12, pp. 96-101, 1999
17.	Sparano, "Cardiac Toxicity of Trastuzumab (Herceptin): Implications for the Design of Adjuvant Trials", <i>Seminars in Oncology</i> , Vol. 28, No. 1, Suppl. 3, pp. 20-27, 2001
18.	Chien, "Myocyte Survival Pathways and Cardiomyopathy: Implications for Trastuzumab Cardiotoxicity", <i>Seminars in Oncology</i> , Vol. 27, No. 6, Suppl. 11, pp. 9-14, 2000
19.	Schnitt, "Breast Cancer in the 21 st Century: New Opportunities and New Challenges", <i>Modern Pathology</i> , Vol. 14, No. 3, pp. 213-218, 2001
20.	Untch, et al., "Anthracycline and Herceptin® als neue Therapieoption beim metastasierten Mammakarzinom", <i>Onkologie</i> , 23 (suppl 2):15-19, 2000
21.	Schaller, et al., "Therapy of metastatic breast cancer with humanized antibodies against the HER2 receptor protein", <i>J. Cancer Res. Clin Oncol.</i> , Vol. 125, pp. 520-524, 1999
22.	Doroshov, et al., "Reactive Oxygen Metabolism Induced by Trastuzumab (Herceptin®) in Human Breast Cancer Cells", <i>Molecular Biology</i> , 29, #4145
23.	Mladosić, et al., "Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane", <i>Neoplasma</i> , Vol. 48, No. 1, pp. 61-99, 2001
24.	Anderson, "Which goes first, the electron or the proton?", <i>Redox Report</i> , Vol. 5, No. 6, Commentary
25.	Kwok, et al., "The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity", <i>Redox Report</i> , Vol. 5, No. 6, pp. 317-324, 2000
26.	Lopez, "Dexrazoxane - Attualità e prospettive nella protezione dalla cardiotossicità indotta da chemioterapia", <i>Clin. Ter.</i> , 150:37-49, 1999
27.	Ferrans, et al., "Pathogenesis and Prevention of Doxorubicin Cardiomyopathy", <i>Cardiology</i> , Vol. 89, No. 10, pp. 928-937, 1997
28.	Rosing, et al., "Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)", <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , Vol. 24, No. 1, pp. 69-77, 1999
29.	Baldwin, et al., "Dose-Independent Pharmacokinetics of the Cardioprotective Agent Dexrazoxane in Dogs", <i>Biopharmaceutics & Drug Disposition</i> , Vol. 17, pp. 541-550, 1996
30.	Kosty, et al., "High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study - Cancer and Leukemia Group B 9631", <i>Lung Cancer</i> , Vol. 34, pp. 289-295, 2001
31.	Weiss, et al., "Dexrazoxane (ICRF-187)", <i>Gen. Pharmac.</i> , Vol. 32, No. 1, pp. 155-158, 1999
32.	Hasinoff, et al., "Relative Plasma Levels of the Cardioprotective Drug Dexrazoxane and its Two Active Ring-Opened Metabolites in the Rat", <i>Drug Metabolism and Disposition</i> , Vol. 27, No. 2, 1999
33.	Seymour, et al., "Use of dexrazoxane as a Cardioprotectant in Patients Receiving Doxorubicin or Epirubicin Chemotherapy for the Treatment of Cancer", <i>The Provincial Systemic Treatment Disease Site Group, Cancer Prev. Control</i> , 3(2):145-59, 1999 - Abstract Only
34.	Kvina, et al., "Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect", <i>Neoplasma</i> , Vol. 44, No. 2, pp. 97-99, 1997

Handwritten signature 2/24/05

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900



EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>2/24/05</i>
--------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

RECEIVED

JUN 28 2002

TECH CENTER 1600/2900

[illegible]

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE